15-Deoxy-Δ12,14-Prostaglandin J2 inhibits tissue factor expression in human macrophages and endothelial cells: Evidence for ERK1/2 signaling pathway blockade

Thrombosis and Haemostasis

Volumn 88, Issue 3, 2002, Pages 524-532

  Eligini, S ^a   Banfi, C ^a   Brambilla, M ^a   Camera, M ^a   Barbieri, S S ^a   Poma, F ^a   Tremoli, E ^a   Colli, Susanna ^a  

^a Dept of Pharmacological Sciences ^*  (Italy)

Author keywords

Cyclopentenone prostaglandins; Endothelial cells; Inflammation; Macrophages; Thrombosis; Tissue factor

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; BACTERIUM LIPOPOLYSACCHARIDE; CYCLOPENTENONE DERIVATIVE; CYTOKINE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN J2; PROTEIN; THROMBOPLASTIN; 15 DEOXY DELTA(12,14) PROSTAGLANDIN J2; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J2; DRUG DERIVATIVE; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; PROSTAGLANDIN D2; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG POTENCY; DRUG TARGETING; ENDOTHELIUM CELL; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; INFLAMMATION; MACROPHAGE; MOLECULAR DYNAMICS; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOSIS; BIOSYNTHESIS; CYTOLOGY; DRUG ANTAGONISM; METABOLISM; TRANSACTIVATION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

DOWN-REGULATION; ENDOTHELIUM, VASCULAR; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PROSTAGLANDIN D2; THROMBOPLASTIN; TRANS-ACTIVATION (GENETICS); TUMOR NECROSIS FACTOR-ALPHA; UMBILICAL VEINS;

EID: 0036714972     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613247     Document Type: Article

References (67)

1. The structural biology of expression and function of tissue factor
2. The role of tissue factor in the production of thrombin
3. Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal E. coli sepsis
4. Neutrophils express tissue factor in a monkey model of sepsis
5. Introduction: Are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?
6. Tissue factor pathway inhibitor (TFPI) reduces mortality from E. coli septic shock
7. 100 Escherichia coli
8. Tissue factor pathway of coagulation: Factor VII, tissue factor, and tissue factor pathway inhibitor
9. Atherosclerosis: An inflammatory disease
10. Immune mechanisms in atherosclerosis
11. Inflammatory pathways in atherosclerosis and acute coronary syndromes
12. Plaque disruption and thrombosis: Potential role of inflammation and infection
13. Inflammation and thrombosis: The clot thickens
14. Atheroma: More than mush
15. Tissue factor in atherosclerosis
16. Inducible cyclooxygenase may have anti-inflammatory properties
17. Role of cyclopentenone prostaglandins in rat carrageenin pleurisy
18. 2
19. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
20. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
21. Prostaglandin D2 inhibits inducible nitric oxide synthase expression in rat vascular smooth muscle cells
22. 2
23. 2 inhibits multiple steps in the NF-κB signaling pathway
24. Regulation of the tissue factor gene
25. Rel/NF-κB/IκB family: Intimate tales of association and dissociation
26. Increased thrombogenic potential of human monocyte-derived macrophages spontaneously transformed into foam cells
27. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria
28. Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs
29. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
30. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei
31. An evaluation of the Coomassie Brilliant Blue G-250 dye-binding method for quantitative protein determination
32. Oxidized low density lipoprotein suppresses expression of inducible cyclooxygenase in human macrophages
33. Thrombin regulates tissue factor and thrombomodulin mRNA levels and activities in human saphenous vein endothelial cells by distinct mechanisms
34. Vastatins inhibit tissue factor in cultured human macrophages: A novel mechanism of protection against atherothrombosis
35. The nuclear receptors peroxisome proliferator-activated receptor α and apolipoprotein A-I expression by fibrates
36. 2 in activated murine macrophages
37. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase
38. 2 inhibition of NF-κB-DNA binding through covalent modification of the p50 subunit
39. 2 is a ligand for the adipocyte determination factor PPARγ
40. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation
41. PPARγ-dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation
42. Transforming growth factor-β1 (TGFβ1) and TGFβ2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-γ
43. The stable prostacyclin analogue, Iloprost, and prostaglandin E1 inhibit monocyte procoagulant activity in vitro
44. The peroxisome proliferator-activated receptor γ (PPARγ) as a regulator of monocyte/macrophage function
45. Regulation of the tissue factor gene in human monocytic cells: Role of AP-1, NF-κB/Rel, and Sp1 proteins in uninduced andlipopolysaccharide-induced expression
46. Regulation of the tissue factor promoter in endothelial cells. Binding of NF-κB-, AP-1-, and Sp1-like transcription factors
47. Salicylates inhibit lipopolysaccharide-induced transcriptional activation of the tissue factor gene in human monocytic cells
48. Protease inhibitors block lipopolysaccharide induction of tissue factor gene expression in human monocytic cells by preventing activation of c-Rel/p65 heterodimers
49. Pyrrolidine dithiocarbamate abrogates tissue factor (TF) expression by endothelial cells: Evidence implicating nuclear factor-κB in TF induction by diverse agonists
50. PPARα activators inhibit tissue factor expression and activity in human monocytes
51. 12, 14 PGJ2 induces procoagulant activity in cultured human endothelial cells
52. 12, 14-prostaglandin J2 on glutathione induction and apoptosis in human endothelial cells
53. Post-transcriptional regulation of macrophage tissue factor expression by anti-oxidants
54. Specificity, diversity, and convergence in VEGF and TNF-α signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells
55. Lipopolysaccharide activation of the MEK-ERK1/2 pathway in human monocytic cells mediates tissue factor and tumor necrosis factor α expression by inducing Elk-1 phosphorylation and Egr-1 expression
56. Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages
57. Cyclopentenone prostaglandins as potential inducers of intracellular oxidative stress
58. Function and regulation of prostaglandin synthase-2
59. The use of cervicular fluid prostaglandin E2 levels as a predictor of periodontal attachment loss
60. Prostaglandin J2 anti-tumour and anti-viral activities and the mechanisms involved
61. 12, 14-prostaglandin J2: A prostaglandin D2 metabolite generated during inflammatory processes
62. Thrombogenic potential of human coronary atherosclerotic plaque
63. Histopathologic comparison of human coronary in-stent and post-ballon angioplasty restenotic tissue
64. Tissue factor expression in coronary circulation as a prognostic factor for late restenosis after coronary angioplasty
65. Tissue factor as a therapeutic target in coronary syndromes
66. 12, 14-prostaglandin J2 is associated with enhanced inflammatory response and restenosis after PTCA